Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraabdominal Infections | 9 | 2025 | 10 | 1.940 |
Why?
|
| Cross Infection | 3 | 2025 | 9 | 1.320 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2025 | 20 | 1.310 |
Why?
|
| Anti-Bacterial Agents | 6 | 2025 | 66 | 1.130 |
Why?
|
| Humans | 27 | 2025 | 2957 | 0.930 |
Why?
|
| Candidiasis | 1 | 2025 | 1 | 0.920 |
Why?
|
| Female | 19 | 2025 | 1724 | 0.890 |
Why?
|
| Intensive Care Units | 2 | 2024 | 33 | 0.880 |
Why?
|
| Antimicrobial Stewardship | 4 | 2025 | 9 | 0.870 |
Why?
|
| Medical Order Entry Systems | 4 | 2025 | 8 | 0.720 |
Why?
|
| Adult | 13 | 2025 | 794 | 0.700 |
Why?
|
| Middle Aged | 9 | 2025 | 792 | 0.650 |
Why?
|
| Male | 11 | 2025 | 1860 | 0.620 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 8 | 0.540 |
Why?
|
| Aged | 9 | 2025 | 956 | 0.510 |
Why?
|
| Genomics | 3 | 2025 | 10 | 0.500 |
Why?
|
| Nursing Homes | 3 | 2025 | 9 | 0.430 |
Why?
|
| Pregnancy | 8 | 2024 | 50 | 0.430 |
Why?
|
| Chicago | 2 | 2025 | 160 | 0.420 |
Why?
|
| Long-Term Care | 2 | 2025 | 5 | 0.380 |
Why?
|
| Skin | 3 | 2025 | 22 | 0.370 |
Why?
|
| Child | 7 | 2024 | 197 | 0.360 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2024 | 6 | 0.360 |
Why?
|
| United States | 7 | 2024 | 243 | 0.340 |
Why?
|
| Chlorhexidine | 4 | 2024 | 12 | 0.340 |
Why?
|
| Hospitalization | 6 | 2025 | 49 | 0.270 |
Why?
|
| Diagnostic Imaging | 5 | 2024 | 12 | 0.270 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2024 | 8 | 0.250 |
Why?
|
| Carrier State | 2 | 2024 | 9 | 0.250 |
Why?
|
| Infection Control | 2 | 2024 | 8 | 0.250 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 1 | 0.230 |
Why?
|
| Genome, Fungal | 1 | 2025 | 1 | 0.230 |
Why?
|
| Phylogeny | 1 | 2025 | 4 | 0.230 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2025 | 1 | 0.230 |
Why?
|
| Air Microbiology | 1 | 2025 | 2 | 0.220 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 2 | 0.220 |
Why?
|
| Environmental Monitoring | 1 | 2025 | 3 | 0.220 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 15 | 0.220 |
Why?
|
| Feces | 1 | 2024 | 6 | 0.220 |
Why?
|
| Blood Culture | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholangitis | 1 | 2024 | 1 | 0.220 |
Why?
|
| Abdominal Abscess | 1 | 2024 | 1 | 0.220 |
Why?
|
| Cholecystitis, Acute | 1 | 2024 | 1 | 0.220 |
Why?
|
| Rectum | 1 | 2024 | 7 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 9 | 0.220 |
Why?
|
| Epidemiological Monitoring | 1 | 2024 | 7 | 0.220 |
Why?
|
| Appendicitis | 1 | 2024 | 3 | 0.220 |
Why?
|
| Patient Discharge | 1 | 2024 | 22 | 0.210 |
Why?
|
| Diverticulitis | 1 | 2024 | 5 | 0.210 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 3 | 0.210 |
Why?
|
| Health Facilities | 1 | 2024 | 7 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2024 | 4 | 0.210 |
Why?
|
| Pneumonia | 1 | 2024 | 8 | 0.210 |
Why?
|
| Reimbursement, Incentive | 1 | 2024 | 2 | 0.210 |
Why?
|
| Clostridium Infections | 1 | 2023 | 6 | 0.200 |
Why?
|
| Candida | 1 | 2023 | 1 | 0.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 6 | 0.180 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 12 | 0.180 |
Why?
|
| beta-Lactamases | 2 | 2025 | 8 | 0.160 |
Why?
|
| Bacterial Proteins | 2 | 2025 | 10 | 0.160 |
Why?
|
| Baths | 2 | 2024 | 7 | 0.160 |
Why?
|
| Disinfection | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mupirocin | 1 | 2019 | 2 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 567 | 0.140 |
Why?
|
| Hospitals | 2 | 2025 | 19 | 0.110 |
Why?
|
| Acute Disease | 2 | 2024 | 26 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2024 | 51 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 9 | 0.110 |
Why?
|
| Klebsiella Infections | 1 | 2014 | 5 | 0.100 |
Why?
|
| Klebsiella pneumoniae | 1 | 2014 | 5 | 0.100 |
Why?
|
| Public Health | 2 | 2024 | 8 | 0.090 |
Why?
|
| California | 2 | 2024 | 13 | 0.090 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 6 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2025 | 3 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 3 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 3 | 0.060 |
Why?
|
| Microbiota | 1 | 2025 | 5 | 0.060 |
Why?
|
| Hospitals, Community | 1 | 2024 | 2 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2024 | 2 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 3 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2024 | 3 | 0.050 |
Why?
|
| Skin Care | 1 | 2024 | 3 | 0.050 |
Why?
|
| Length of Stay | 1 | 2024 | 15 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2024 | 8 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 97 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2024 | 7 | 0.050 |
Why?
|
| Benchmarking | 1 | 2024 | 3 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 142 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 9 | 0.050 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 2 | 0.040 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 3 | 0.040 |
Why?
|
| Prevalence | 1 | 2019 | 39 | 0.040 |
Why?
|
| Hygiene | 1 | 2019 | 2 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 2 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 10 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 49 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 147 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 1997 | 3 | 0.030 |
Why?
|
| HIV-1 | 1 | 1997 | 59 | 0.030 |
Why?
|
| HIV Infections | 1 | 1997 | 103 | 0.030 |
Why?
|
| Asphyxia Neonatorum | 1 | 1984 | 1 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1984 | 12 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1984 | 20 | 0.010 |
Why?
|
| Heating | 1 | 1997 | 3 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 3 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1997 | 3 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 4 | 0.010 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 5 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 5 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1997 | 4 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 11 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1997 | 8 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 11 | 0.010 |
Why?
|
| Monocytes | 1 | 1997 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 30 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 20 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 119 | 0.010 |
Why?
|
| Lactates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Pyruvates | 1 | 1984 | 1 | 0.000 |
Why?
|
| Catecholamines | 1 | 1984 | 2 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 6 | 0.000 |
Why?
|
| Liver | 1 | 1984 | 6 | 0.000 |
Why?
|
| Glycogen | 1 | 1984 | 6 | 0.000 |
Why?
|
| Insulin | 1 | 1984 | 9 | 0.000 |
Why?
|
| Glucagon | 1 | 1984 | 4 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1984 | 81 | 0.000 |
Why?
|
| Rats | 1 | 1984 | 234 | 0.000 |
Why?
|
| Animals | 1 | 1984 | 1050 | 0.000 |
Why?
|